FDA Grants Solid Biosciences Orphan Drug Designation For SGT-212 For Friedreich's Ataxia
Benzinga Newsdesk 9 months ago
BiotechNewsFDAGeneral
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026,
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -
- Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, subject to participant enrollment -